Human ADA2 deficiency is characterized by the absence of an intracellular hypoglycosylated form of adenosine deaminase 2

This study identifies a previously uncharacterized intracellular, hypoglycosylated, low-molecular-weight form of ADA2 localized to lysosomes, the absence of which in macrophages serves as a specific cellular biomarker for DADA2 and correlates with reduced enzymatic activity and variant pathogenicity.

The Gist

The Big Picture: A Broken Factory and a Missing Delivery Truck

Imagine your body is a massive city, and your immune system is the police force keeping the city safe. One of the most important tools this police force uses is a protein called ADA2. Think of ADA2 as a specialized delivery truck that carries a very important package (an enzyme) to specific locations to keep inflammation (a type of city riot) under control.

DADA2 is a disease where people are born with a broken blueprint for building these trucks. Usually, doctors thought the problem was simply that the trucks weren't being built at all, or they were broken before they could leave the factory.

However, this new study discovered something much more specific and fascinating: The problem isn't just that the trucks are missing; it's that the broken trucks never get their final "polish" and "license plate" before they leave the factory. Because of this, they get stuck in the factory basement and never reach the streets where they are needed.

---

The Story of the Two Types of Trucks

To understand the discovery, we need to look at how a healthy truck (Wild-Type ADA2) is made versus a broken one (Mutant ADA2).

1. The Healthy Factory (Healthy People)

In a healthy person, the factory (the cell) builds the ADA2 truck in two stages:

• Stage 1 (The Rough Draft): The truck is built with a bulky, heavy protective coating (called a "glycan" or sugar coat). Let's call this the Heavy Truck (HMW). It's big and clunky.
• Stage 2 (The Polish): Before the truck leaves the factory, it goes through a special "polishing station" (the Golgi and Lysosome). Here, workers trim off the extra heavy coating. The truck becomes lighter and sleeker. Let's call this the Light Truck (LMW).
  • The Twist: The study found that this Light Truck doesn't just leave the factory; it actually stays inside the cell's "garage" (the lysosome) to do a specific job there. It's like a specialized maintenance vehicle that stays in the garage to fix things from the inside.

2. The Broken Factory (DADA2 Patients)

In people with DADA2, the blueprint for the truck has a typo.

• The factory builds the Heavy Truck (HMW), but because of the typo, the truck gets stuck in the "Quality Control" line at the very beginning of the factory (the Endoplasmic Reticulum).
• The truck never makes it to the "polishing station." It never gets trimmed down.
• The Result: The factory is full of heavy, clunky, unpolished trucks that are stuck in the basement. The Light Truck (LMW) is completely missing.
• Because the Light Truck is missing, the "garage" (lysosome) has no maintenance vehicle, and the "streets" (bloodstream) don't get the proper signal to stop the riots (inflammation).

---

The Detective Work: How They Found the Clue

The researchers acted like detectives trying to solve a mystery. They looked at cells from 10 patients with DADA2 and compared them to healthy people.

1. The Weight Check: They weighed the proteins. Healthy cells had two types: Heavy and Light. DADA2 cells only had Heavy.
2. The "Sugar" Test: They realized the difference in weight was due to the "sugar coating." In healthy cells, the sugar was trimmed off to make the Light Truck. In DADA2 cells, the sugar was never trimmed.
3. The Location Hunt: They used a microscope to see where the trucks were hiding.
   • The Light Truck was found deep inside the cell's "garage" (the lysosome).
   • The Heavy Truck (the broken one) was stuck in the factory's loading dock.
4. The "Rescue" Experiment: They took a healthy, heavy truck from outside the cell and dropped it into a DADA2 cell. Amazingly, the DADA2 cell's machinery could trim it down into a Light Truck! This proved that the DADA2 cells have the tools to do the job; they just can't do it on their own broken trucks.

---

Why This Matters: A New Way to Diagnose

Before this study, doctors diagnosed DADA2 by checking if the enzyme worked in the blood. But sometimes, a broken truck might still have a little bit of engine power left, making it hard to tell if it's truly broken.

The New Clue:
This study found that if the "Light Truck" (LMW-ADA2) is missing, the patient definitely has the disease.

• It's like checking a car's license plate. If the car has the heavy, untrimmed coating, it's a broken car. If it has the sleek, trimmed coating, it's a healthy car.
• This "Light Truck" marker is a much more reliable way to spot the disease than just measuring engine power.

The Takeaway

This paper changes how we see the disease. It's not just about the enzyme stopping working; it's about the delivery system breaking down. The broken proteins get stuck in the factory, never getting the "trim" they need to become the functional "Light Truck" that lives in the cell's garage.

By understanding that the absence of this specific "Light Truck" is the hallmark of the disease, doctors might be able to diagnose patients faster and more accurately, even in tricky cases where the enzyme still seems to work a little bit. It's a classic case of finding the missing piece of the puzzle that explains why the whole machine is failing.

Technical Summary

1. Problem Statement

Deficiency of Adenosine Deaminase 2 (DADA2) is an autoinflammatory disease caused by biallelic pathogenic variants in the ADA2 gene. While the disease is characterized by impaired extracellular adenosine deaminase activity, the precise pathomechanisms remain unclear.

• The Gap: Previous research focused on the loss of extracellular enzyme activity. However, a recent hypothesis suggests ADA2 may also have an intracellular, lysosomal function.
• The Challenge: Pathogenic ADA2 variants are diverse (over 600 listed), and their biochemical consequences are not fully understood in a physiological context. Most prior studies used overexpression systems (HEK293T) that do not reflect endogenous protein trafficking or glycosylation patterns found in primary immune cells. There is no established cellular biomarker to distinguish pathogenic variants from benign ones beyond enzyme activity assays, which can be inconclusive for variants with residual activity.

2. Methodology

The authors employed a multi-faceted approach combining primary human cells, cell line models, and biochemical fractionation:

• Primary Cells: Analyzed monocyte-derived macrophages (HMDM) from 10 DADA2 patients and healthy controls (HC).
• Cell Line Models:
  • HEK293T: Used for transient overexpression of 34 different ADA2 variants (including pathogenic and benign) to screen protein expression and glycosylation.
  • U-937 & THP-1: Monocytic cell lines used for stable transduction (CRISPR/Cas9 generated ADA2 knockout lines were reconstituted with variants) to study endogenous-like trafficking.
• Biochemical Techniques:
  • Western Blotting & Capillary Electrophoresis (Wes): To distinguish molecular weight differences between High-Molecular-Weight (HMW) and Low-Molecular-Weight (LMW) forms.
  • Glycan Processing Inhibition: Used specific inhibitors (Tunicamycin, Castanospermine, Kifunensine, Swainsonine, Brefeldin A, Monensin) to map the secretory pathway and glycosylation steps.
  • Enzymatic Deglycosylation: PNGase F (removes all N-glycans), Endo H (removes high-mannose glycans), and $\alpha$-mannosidase to characterize glycan structures.
  • Subcellular Fractionation: Isolated lysosomal, cytosolic, and membrane fractions.
  • Immunofluorescence Microscopy: Co-staining with lysosomal (LAMP1), Golgi (GM130), and ER (Calnexin) markers.
  • Mass Spectrometry (IP-MS): Analyzed protein interactors of wild-type (WT) vs. mutant (p.R169Q) ADA2.
  • Enzyme Activity Assays: Measured adenosine deaminase activity in cell lysates and supernatants.

3. Key Contributions & Results

A. Discovery of a Novel Intracellular Glycoform (LMW-ADA2)

• Observation: Healthy control macrophages express two intracellular forms of ADA2: a High-Molecular-Weight (HMW) form (60 kD) and a Low-Molecular-Weight (LMW) form (57 kD).
• DADA2 Phenotype: Macrophages from DADA2 patients express only the HMW form; the LMW form is completely absent.
• Glycosylation Status:
  • The LMW form is hypoglycosylated compared to the secreted HMW form.
  • It is not a completely deglycosylated protein (which would be ~53 kD after PNGase F treatment) but represents a specific intermediate state.
  • The LMW form is generated by $\alpha$-mannosidase-mediated trimming of N-glycans.

B. Localization and Trafficking Pathway

• Lysosomal Localization: Immunofluorescence and subcellular fractionation confirmed that LMW-ADA2 localizes to the lysosomes.
• Trafficking Mechanism:
  • WT ADA2 undergoes ER quality control (glucosidase trimming) and moves to the Golgi.
  • In the Golgi and lysosomes, $\alpha$-mannosidases (specifically Class I and Class II, including lysosomal $\alpha$-mannosidase) trim the glycans to create the LMW form.
  • Pathogenic Variants: Mutant ADA2 proteins are retained in the ER (or early Golgi) due to misfolding. They fail to undergo the specific $\alpha$-mannosidase trimming required to generate the LMW form. Consequently, they remain as HMW-ADA2 and are either degraded or fail to reach the lysosome.
• Exogenous Uptake: The study demonstrated that ADA2-deficient cells can take up secreted WT HMW-ADA2 from the extracellular space and process it intracellularly into the LMW-lysosomal form.

C. Correlation with Pathogenicity and Enzyme Activity

• Biomarker Validation: The authors analyzed 34 ADA2 variants. The absence of LMW-ADA2 strongly correlated with:
  1. Reduced or absent adenosine deaminase enzyme activity.
  2. Clinical classification as pathogenic.
• Superiority over Enzyme Activity Alone: Some variants (e.g., p.P344L) showed residual enzyme activity (>25%) but lacked LMW-ADA2, suggesting they are pathogenic despite "normal" enzyme assays. Conversely, the presence of LMW-ADA2 generally indicated a benign or less severe variant.
• Interactome: Mutant ADA2 (p.R169Q) showed increased binding to ER chaperones (folding machinery) compared to WT, confirming ER retention, but did not induce significant ER stress in primary monocytes under physiological expression levels.

4. Significance

• Mechanistic Insight: The paper establishes that DADA2 is not just a loss of extracellular enzyme activity but also a failure of intracellular lysosomal processing. It provides the first cellular evidence for the existence of a lysosomal ADA2 form (LMW-ADA2).
• Diagnostic Utility: The absence of LMW-ADA2 serves as a robust cellular biomarker for variant pathogenicity. This is particularly valuable for variants where enzyme activity assays are ambiguous (e.g., variants with residual activity).
• Therapeutic Implications:
  • The finding that exogenous WT ADA2 can be internalized and processed into the functional lysosomal form supports the potential efficacy of enzyme replacement therapies (e.g., PEGylated ADA2). It suggests that administered ADA2 can bypass the genetic defect and restore the missing intracellular lysosomal function.
• Refining Disease Models: The study highlights the limitations of HEK293T overexpression models, which predominantly show the secreted HMW form, and emphasizes the necessity of studying ADA2 in primary immune cells (macrophages) to understand the true pathophysiology.

In conclusion, this study redefines the cellular pathology of DADA2, identifying the absence of a specific lysosomal, hypoglycosylated ADA2 form as the hallmark of the disease and offering a new tool for genetic diagnosis and therapeutic validation.